3-[5-(4-fluorophenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-piperidine-1-carboxylic acid tert-butyl ester | 189442-04-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-[5-(4-fluorophenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-piperidine-1-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl 3-[4-(4-fluorophenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]piperidine-1-carboxylate
• CAS: 189442-04-4
• 化学式: C₂₄H₂₇FN₄O₂
• 分子量: 422.502
• InChiKey: CLNGMCHUKJFCQJ-UHFFFAOYSA-N

物化性质

• 熔点：
  193-194 °C
• 沸点：
  595.5±50.0 °C(Predicted)
• 密度：
  1.212±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  71.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-[5-(4-fluorophenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-piperidine-1-carboxylic acid tert-butyl ester 以 四氢呋喃 为溶剂， 生成 3-[5-(4-fluorophenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-1-methyl-piperidine
  参考文献：
  名称：

  Substituted imidazoles having anti-cancer and cytokine inhibitory

  摘要：

  公式I所代表的化合物如下所示：##STR1##。其中，AR代表含有6-10个原子的芳香基团；而##STR2##代表一个仅含有一个N原子的4至6元非芳香杂环。还包括一种药物组合物。还包括治疗癌症和细胞因子介导疾病的方法。

  公开号：

  US05717100A1
• 作为产物：
  描述：

  二碳酸二叔丁酯 、 3-哌啶甲酸 在 sodium hydroxide 作用下， 以 1,4-二氧六环 为溶剂， 生成 3-[5-(4-fluorophenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  US6083949

  摘要：

  公开号：

文献信息

• SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY
  申请人：Merck & Co., Inc.

  公开号：EP0854870B1

  公开（公告）日：2009-06-10
• Design and Synthesis of Potent, Selective, and Orally Bioavailable Tetrasubstituted Imidazole Inhibitors of p38 Mitogen-Activated Protein Kinase
  作者：Nigel J. Liverton、John W. Butcher、Christopher F. Claiborne、David A. Claremon、Brian E. Libby、Kevin T. Nguyen、Steven M. Pitzenberger、Harold G. Selnick、Garry R. Smith、Andrew Tebben、Joseph P. Vacca、Sandor L. Varga、Lily Agarwal、Kim Dancheck、Amy J. Forsyth、Daniel S. Fletcher、Betsy Frantz、William A. Hanlon、Coral F. Harper、Scott J. Hofsess、Matthew Kostura、Jiunn Lin、Sylvie Luell、Edward A. O'Neill、Chad J. Orevillo、Margaret Pang、Janey Parsons、Anna Rolando、Yousif Sahly、Denise M. Visco、Stephen J. O'Keefe

  DOI：10.1021/jm9805236

  日期：1999.6.1

  Novel potent and selective diarylimidazole inhibitors of p38 MAP (mitogen-activated protein) kinase are described which have activity in both cell-based assays of tumor necrosis factor-alpha (TNF-alpha) release and an animal model of rheumatoid arthritis; The SAR leading to the development of selectivity against c-Raf and JNK2 alpha 1 kinases is presented, with key features being substitution of the 4-aryl ring with m-trifluoromethyl and substitution of the 5-heteroaryl ring with a a-amino substituent. Cell-based activity was significantly enhanced by incorporation of a 4-piperidinyl moiety at the 2-position of the imidazole which also enhanced aqueous solubility. In general, oral bioavailability of this class of compounds was found to be poor unless the imidazole was methylated on nitrogen. This work led to identification of 48, a potent (p38 MAP kinase inhibition IC50 0.24 nM) and selective p38 MAP kinase inhibitor which inhibits lipopolysaccharide-stimulated release of TNF-alpha from human blood with an IC50 2.2 nM, shows good oral bioavailability in rat and rhesus monkey, and demonstrates significant improvement in measures of disease progression in a rat adjuvant-induced arthritis model.
• US06083949
  申请人：——

  公开号：——

  公开（公告）日：——
• A METHOD OF TREATING CANCER
  申请人：MERCK & CO., INC.

  公开号：EP0934270A1

  公开（公告）日：1999-08-11
• US6083949A
  申请人：——

  公开号：US6083949A

  公开（公告）日：2000-07-04